Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.

Nature medicine - 1 Jun 2011

Giamas Georgios, Filipović Aleksandra, Jacob Jimmy, Messier Walter, Zhang Hua, Yang Dongyun, Zhang Wu, Shifa Belul Assefa, Photiou Andrew, Tralau-Stewart Cathy, Castellano Leandro, Green Andrew R, Coombes R Charles, Ellis Ian O, Ali Simak, Lenz Heinz-Josef, Stebbing Justin

Abstract excerpt

Therapies targeting estrogen receptor α (ERα, encoded by ESR1) have transformed the treatment of breast cancer. However, large numbers of women relapse, highlighting the need for the discovery of new regulatory targets modulating ERα pathways. An siRNA screen identified kinases whose silencing alters the estrogen response including those previously implicated in regulating ERα activity (such as mitogen-activated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Gene Expression Regulation, Neoplastic

Share to Mice, Nude

Share to Neoplasm Transplantation

Share to RNA, Small Interfering

Share to Tamoxifen

Source

Identifiers

PMID: 21602804
DOI: 10.1038/nm.2351

Genes

LMTK3
ESR1
FOXO3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.PMID 21602804Read ↗

LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome.Semantic proximity Read ↗

Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast CancerSemantic proximity Read ↗

High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.Semantic proximity Read ↗

Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancerSemantic proximity Read ↗

Investigation of the function of LMTK3 in breast cancer invasion and transcriptional regulationSemantic proximity Read ↗

ETS transcription factor ELK3 in human cancers: An emerging therapeutic targetSemantic proximity Read ↗

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Semantic proximity Read ↗

Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.Semantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast CancerSemantic proximity Read ↗

Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancerSemantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.